» Authors » Julien Boudreau

Julien Boudreau

Explore the profile of Julien Boudreau including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 2
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Correll C, Cutler A, Laliberte F, Germain G, MacKnight S, Boudreau J, et al.
Ann Gen Psychiatry . 2025 Jan; 24(1):5. PMID: 39871357
Background: Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from...
2.
Mannino D, Weng S, Germain G, Boudreau J, Tardif-Samson A, Forero-Schwanhaeuser S, et al.
Adv Ther . 2024 Dec; 42(2):1131-1146. PMID: 39731707
Introduction: Chronic obstructive pulmonary disease (COPD) is associated with exacerbations which can reduce quality of life and increase mortality. Single-inhaler triple therapy (SITT) is recommended for maintenance treatment of COPD...
3.
Cutler A, Laliberte F, Germain G, MacKnight S, Boudreau J, Wade S, et al.
J Med Econ . 2024 Nov; 27(1):1472-1484. PMID: 39531329
Aims: To evaluate the healthcare resource utilization (HRU) and costs of patients who initiated cariprazine as their first versus subsequent atypical antipsychotic (AA) following a bipolar I disorder (BP-I) diagnosis....
4.
Casale T, Corbridge T, Germain G, Laliberte F, MacKnight S, Boudreau J, et al.
Allergy Asthma Clin Immunol . 2024 Mar; 20(1):25. PMID: 38532489
Background: Systemic corticosteroid (SCS) use remains widespread among patients with severe asthma, despite associated complications. Objective: Evaluate the association between cumulative SCS exposure and SCS-related complications in severe asthma. Methods:...
5.
Zhdanava M, Zhao R, Manceur A, Ding Z, Boudreau J, Kachroo S, et al.
J Manag Care Spec Pharm . 2024 Feb; 30(2):141-152. PMID: 38308626
Background: Chronic corticosteroid use is common in ulcerative colitis (UC); however, real-world evidence of its burden to the health care system is limited. Objective: To quantify chronic corticosteroid use burden...
6.
Zhdanava M, Zhao R, Manceur A, Ding Z, Boudreau J, Kachroo S, et al.
J Am Pharm Assoc (2003) . 2023 Nov; 64(2):386-394.e10. PMID: 37956768
Background: Chronic corticosteroid (CS) use is associated with complications, but estimates of the economic and clinical burden in patients with Crohn's disease (CD) are lacking. Objective: To estimate the burden...
7.
Berger J, Ashton V, Laliberte F, Germain G, Bookhart B, Lejeune D, et al.
Adv Ther . 2023 Jan; 40(3):1224-1241. PMID: 36658454
Introduction: The healthcare resource utilization (HRU) and costs of oral anticoagulant-naïve patients with non-valvular atrial fibrillation (NVAF) and diabetes initiated on rivaroxaban or warfarin in the United States (US) has...